ArriVent BioPharma, Inc.
AVBP$948M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEWTOWN SQUARE52 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AVBP News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
Firmonertinib
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
furmonertinib 240 mg oral, daily | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - | - |
Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply